Scott C F, Colman R W
Department of Medicine, Temple University School of Medicine, Philadelphia, PA 19140.
J Lab Clin Med. 1988 Jun;111(6):708-14.
Traditionally, factor XI has been determined in the clinical laboratory by a modified activated partial thromboplastin time assay (aPTT) with factor XI-deficient plasma as the substrate. Coagulant assays, however, have high coefficients of variation. We previously developed a chromogenic assay for factor XI that required equipment not normally found in a clinical laboratory. We now present a modification of that assay, which is performed in 96-well microplates and can be done in any clinical laboratory or physician's office. Plasma is subjected to a brief acidification to inactivate most of the plasma protease inhibitors. Soybean trypsin inhibitor is included to stabilize the factor XIa that is generated. Kaolin is used as the contact activating surface, and the chromogenic substrate, S-2366, is used to measure the factor XIa that is formed. Results of the assay, performed in three groups of subjects, correlate well with results of the coagulant assay as performed in our laboratory and clearly differentiate between total factor XI deficiency and the deficiency of any of the other contact proteins. Unlike coagulation assays, the chromogenic assay is not influenced by the presence of heparin. Furthermore, it is not affected by lupus anticoagulants, which are antibodies directed against acidic phospholipids. Two plasma samples from patients with acquired factor XI inhibitors showed dissociation between coagulant and amidolytic activity, suggesting that the antibodies were not primarily directed toward the active site of factor XIa, which is responsible for its amidolytic activity. In contrast, patients with severe congenital deficiency of factor XI showed no activity by either assay.
传统上,临床实验室通过以缺乏因子XI的血浆为底物的改良活化部分凝血活酶时间测定法(aPTT)来测定因子XI。然而,凝血测定法的变异系数很高。我们之前开发了一种用于因子XI的发色底物法,该方法需要临床实验室中通常没有的设备。我们现在展示该方法的一种改良,它在96孔微孔板中进行,并且可以在任何临床实验室或医生办公室完成。血浆经过短暂酸化以灭活大部分血浆蛋白酶抑制剂。加入大豆胰蛋白酶抑制剂以稳定生成的因子XIa。高岭土用作接触激活表面,发色底物S-2366用于测量形成的因子XIa。在三组受试者中进行的该测定结果与我们实验室进行的凝血测定结果密切相关,并且能够清楚地区分完全因子XI缺乏症与任何其他接触蛋白的缺乏症。与凝血测定法不同,发色底物法不受肝素存在的影响。此外,它不受狼疮抗凝物的影响,狼疮抗凝物是针对酸性磷脂的抗体。来自获得性因子XI抑制剂患者的两份血浆样本显示凝血活性和酰胺水解活性之间存在解离,这表明抗体并非主要针对负责其酰胺水解活性的因子XIa的活性位点。相比之下,严重先天性因子XI缺乏症患者的两种测定均未显示活性。